| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
RIVTSEEVIIRDS TFA is a peptide tetramer that targets interactions with neuroplastins, which are multifunctional neuronal adhesion proteins. Neuroplastins play roles in synaptic plasticity, neurite outgrowth, and cell adhesion. The peptide is designed to modulate the function of these proteins, making it a valuable tool for studying neuronal connectivity and synaptic function.
|
|---|---|
| ln Vitro |
In vitro, RIVTSEEVIIRDS TFA is a bioactive peptide tetramer that can be utilized in a variety of biochemical studies. It is particularly useful for investigating the role of neuroplastins in neuronal adhesion and synaptic plasticity. The peptide can be used in binding assays to study protein-protein interactions involving neuroplastins. Detailed cellular activity data have not been reported.
|
| ln Vivo |
In vivo activity data for RIVTSEEVIIRDS TFA have not been reported. As a research peptide, its primary use is in biochemical and cell-based assays to study neuroplastin function. It may be used in ex vivo tissue cultures or in vivo models to investigate synaptic plasticity or neurological disorders, but specific data are lacking.
|
| Enzyme Assay |
A cell-free binding assay for RIVTSEEVIIRDS TFA can be performed using surface plasmon resonance (SPR) or enzyme-linked immunosorbent assay (ELISA). Recombinant neuroplastin protein is immobilized on a sensor chip or plate. Increasing concentrations of the peptide (0.1-100 microM) are flowed over the surface. Binding affinity (Kd) is calculated from the association and dissociation rates. A competition assay with a labeled peptide can determine specificity.
|
| Cell Assay |
RIVTSEEVIIRDS TFA can be used in cell adhesion assays. Neuroblastoma cells (e.g., SH-SY5Y) are seeded in 96-well plates pre-coated with the peptide (10-100 microg/mL). After 1-2 hours of incubation, non-adherent cells are washed away. Adherent cells are quantified by crystal violet staining (absorbance at 595 nm). Alternatively, neurite outgrowth can be assessed by treating primary neurons with the peptide (1-50 microM) for 24-72 hours and measuring neurite length by microscopy.
|
| Animal Protocol |
RIVTSEEVIIRDS TFA can be administered in mouse models of synaptic plasticity or memory. Male C57BL/6 mice (8-10 weeks, n=8 per group) are injected intracerebroventricularly (ICV) or intraperitoneally with RIVTSEEVIIRDS TFA (1-10 mg/kg). Behavioral tests such as the Morris water maze or novel object recognition are performed to assess learning and memory. Brain tissues are collected for immunohistochemistry to evaluate synaptic markers (e.g., PSD-95, synaptophysin).
|
| ADME/Pharmacokinetics |
RIVTSEEVIIRDS TFA has a molecular weight of 1630.72 and the molecular formula C66H114F3N19O25. The powder should be stored sealed, away from moisture, at -80degC for up to 2 years or at -20degC for 1 year. In solution, it is stable for 6 months at -80degC or 1 month at -20degC. Specific PK parameters have not been reported. The TFA salt enhances solubility.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for RIVTSEEVIIRDS TFA are available. As a research-grade peptide derived from natural sequences, it is expected to have low inherent toxicity. Standard safety precautions for handling peptides should be followed. Formal toxicology studies (e.g., acute, sub-chronic) have not been published.
|
| References |
[1]. Philip Beesley, et al. The neuroplastins: multifunctional neuronal adhesion molecules--involvement in behaviour and disease. Adv Neurobiol. 2014;8:61-89.
|
| Additional Infomation |
RIVTSEEVIIRDS TFA is a research-grade peptide and is not approved for clinical use. It is a peptide tetramer used for various biochemical studies, particularly in neuroplastin research. This product is for research use only and not for human therapeutic applications. Store as lyophilized powder at -20degC or -80degC.
|
| Molecular Formula |
C66H114F3N19O25
|
|---|---|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~66.67 mg/mL (~40.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
